Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2020
Dechra completes acquisition of worldwide Osurnia rights
Dechra Pharmaceuticals completed its acquisition of the worldwide rights to the Osurnia product portfolio from Elanco Animal Health for USD 135.0 million (£104.7 million).
2020
Dechra agrees to acquire worldwide rights to Osurnia
Dechra announced that it had agreed terms to acquire the worldwide rights to Elanco's Osurnia product portfolio for USD 135.0 million. Completion was expected before the end of June 2020, subject to conditions and regulatory approvals.